Global Lumbar Degenerative Disc Disease Market - 2023-2030

Global Lumbar Degenerative Disc Disease Market - 2023-2030

Global Lumbar Degenerative Disc Disease Market reached US$ 12.1 billion in 2022 and is expected to reach US$ 21.3 billion by 2030, growing with a CAGR of 7.4% during the forecast period 2023-2030.

Between every vertebral body of the spine are pads of fibrocartilage-based structures that deliver support, flexibility, and little load-sharing, comprehended as the intervertebral discs. A disturbance of the normal architecture of these round discs can lead to a disc herniation or a protrusion of the inner nucleus pulposus, perhaps spreading strain to the spinal cord or nerve root and resulting in radiating pain and typical locations of weakness.

Little more than 90% of herniated discs arise at the L4-L5 or the L5-S1 disc space, which will impinge on the L4, L5, or S1 nerve root. This compression elicits radiculopathy into the posterior leg and dorsal foot. Degenerative disc disorder is an aging-related condition of the discs between the vertebrae resulting in cushioning loss, fragmentation, and herniation. In recent years the Regenerative medicine approaches for treating degenerative disc disease have drawn more attention in recent years.

The growing spinal injuries, FDA authorizations, market developments including mergers, acquisitions, products introductions, growing awareness among other factors are expected to boost the global lumbar degenerative disc disease market growth in the forecast period. Further, the growing cases of geriatric population and research activities are also expected to contribute to the global market growth in the forecast period.

Dynamics

Increasing Product Authorization

The increasing product authorization from distinct regulatory authorities is expected to boost the global market growth during the forecast period. For instance, in February 2023, Mesoblast Limited, a multinational leader in allogeneic cellular medicines for inflammatory conditions, obtained the United States Food and Drug Administration’s (FDA) Office of Tissues and Advanced Therapies (OTAT) Regenerative Medicine Advanced Therapy (RMAT) designation for its rexlemestrocel-L indicated for the treatment of chronic low back pain (CLBP) related with disc degeneration, in mixture with hyaluronic acid (HA) as delivery agent for injection into the lumbar disc.

Moreover, in February 2023, DiscGenics Inc. obtained the FDA regenerative medicine progressive therapy designation for its injectable disc cell therapy to treat individuals with symptomatic lumbar degenerative disc disorder. Injectable disc cell therapy (IDCT) has the prospect of improving disc volume, enhancing low back pain, and reducing pain medication use in individuals with lumbar degenerative disc disease.

Increasing Case of Degenerative Disc Disease

The growing cases of degenerative disc disease are expected to boost the global market growth during the forecast period. Approximately 40% of adults above the age of 40 have at least one degenerated vertebral disc and by the age of 80, over 80% of them do. Disc decline is considered a standard element of aging, such as skin wrinkles and gray hair. For instance, according to the data published by the UN in 2022, it is assessed that the percentage of the global inhabitants of individuals aged 65 years and above is projected to increase from 10 percent in 2022 to 16 percent in 2050. With the growing geriatric population, it is anticipated that the number of spinal cord disorders will grow.

Moreover, according to the National Center for Biotechnology Information (NCBI), a whole of 266 million individuals (3.63%) globally were detected with Degenerative Spinal Disc and LBP yearly. Again, according to the Social, Health, and Family Affairs Committee, there are an estimated 330,000 individuals living with spinal cord injury (paraplegia and tetraplegia) in the associate states of the Council of Europe, with almost 11,000 new patients annually. About half of these injuries are the consequence of road accidents and arise at a young age.

Stringent Process and High Cost of Drug Development

The long and stringent procedure for drug development and commercialization with low success probability is expected to hamper the global market growth during the forecast period. For instance, the most evident purpose of clinical investigation is to establish safeness and effectiveness to achieve Food and Drug Administration (FDA) clearance. FDA delivers recommendations to designers regarding what constitutes permitted clinical investments and fair results. Enhancing the drug development approach, particularly by conducting sufficient (meaning delivering more additional data on safeness or effectiveness) and more quick clinical investigations, can encourage innovation in medical product development.

A pharmaceutical corporation pursuing FDA authorization to commercialize a new pharmaceutical drug is required to meet a five-step process: discovery/concept, preclinical research, clinical research, FDA review, and FDA post-market safety monitoring, making it difficult to develop and commercialize the drug product. Further, the large expenditure for new drug development is also expected to hamper the global market growth in the forecast period. For instance, the anticipated cost to develop a new drug including funds expenses and expenses on drugs that fail to achieve market approval has been assessed to vary from less than $1 billion to over $2 billion.

Avabliability of Other Substituent Treatment Option

The availability of other treatment options for Degenerative Disc Disease in individuals also lowers the demand for drug treatment. For instance, physical therapy can benefit in attaining and sustaining optimal fitness of a patient’s backbone and relieving discomfort. The general goal of physical therapy is to specify and instruct individuals on efficient regime approaches to enhance spine-related issues with a focus on reducing existing pain signs, enhancing stability and function, and lowering the recurrence of symptoms.

Physical therapy, with or without other conventional treatments, can usually cure spinal pain, as evidenced by the fact that rarer than one percent of individuals with neck or back problems eventually go on to have spinal surgery. Further, surgical procedures such as Anterior Lumbar Corpectomy and Fusion Surgery, Anterior Lumbar Interbody Fusion (ALIF) Surgery, and Posterior Lumbar Fusion (PLF) among others is also a choice for patients for Degenerative Disc Disease slowing the global market growth during the forecast period.

Segment Analysis

The global lumbar degenerative disc disease market is segmented based on treatment type, route of administration, end-user and region.

Biologics Treatment Type Expected to Dominate Market

Owing to The increasing research activities in biologics treatment are expected to boost the segment market growth dominating the global market during the forecast period. For instance, in January 2023, DiscGenics, Inc., a clinical-stage biopharmaceutical corporation concentrated on developing regenerative cell-based treatments that relieve pain and repair function in patients with degenerative disorders of the spine, reported favorable two-year clinical information from its first-in-human clinical investigation of IDCT (rebonuputemcel), an allogeneic discogenic progenitor cell therapy for lumbar degenerative disc disorder (DDD).

Moreover, in March 2023, an injection that reduces lower back discomfort by assisting injured spinal discs seems to bear sustained advantages, new clinical investigation reports revealed. The majority of patients who received an injection of viable disc allograft supplementation (VIA-Disc) a blend of bone marrow cells and ground-up spinal disc tissue from donors obtained back pain comfort that lasted at least three years. Approximately 60% of patients had a 50% or better progress in their pain three years post-treatment, outcomes indicated, while over 70% retained a greater than 20-point progress in movement and function..

Geographical Penetration

Increasing Cases of Spinal Cord Injury in North America

The increasing number of spinal cord injury cases in North America is expected to boost regional market growth, dominating the global market throughout the forecast period. For instance, according to the National Spinal Cord Injury Statistical Center in 2022, approximately 30% of individuals with spinal cord injury (SCI) were re-hospitalized one or more times in any given year following injury, and out of those re-hospitalized, the duration of hospital visit averages around 18 days and the estimated number of people with spinal cord injury living in the United States in 2021 was approximately 299,000 individuals, with a degree from 253,000 to 378,000. The indirect expenses of SCI averaged USD 82,329 every year in the United States in 2021. Further, the 2021 American Community Survey assessed there were 55,892,014 individuals aged 65 and above in the U.S. out of a total inhabitant of 331,893,745, accounting for 16.8%.

Further, the increasing research funding sustains the regional market growth in the forecast period. For instance, in February 2023, Investigators at Cedars-Sinai obtained $2 million in funding from the California Institute for Regenerative Medicine (CIRM) to design a new cell therapy that aids in enhancing the quality of life for individuals with worsened discs and chronic lower back discomfort.

Russia Ukraine War Impact

In February 2022, Russia unreasonably attacked Ukraine. The bloody conflict in Ukraine has seen several attacks on healthcare institutions, including hospitals and clinics. Since the inception of the war in Ukraine, the healthcare system in some regions has been devastated. As per records, a total of 103 assaults have been documented, including 89 attacks on healthcare institutions and about 13 attacks on healthcare transportation.

When Russia invaded Ukraine, hospitals had to suspend all elective surgeries, including cancer surgery thus, slowing the regional market growth. However, the absence of key market players from this region has not affected the global market in any major way, yet the impact on export of raw Route of Administrations from the war-influenced region has a minimal impact on the global market.

COVID-19 Impact Analysis

During the COVID-19 pandemic, elective and routine examinations and operations were postponed or discontinued because of redirecting aids to additional emergent therapy for extremely sick individuals and to avert the spread and contraction of COVID-19. Further, the workforce was pulled narrow, and healthcare structures witnessed growing turnover rates for full-time and agreement workers, which pushed the system and decreased the capacity to deliver clinical assistance.

Since more beds in wards and intensive care units were assigned to COVID-19 patients, considerable surgical divisions registered a reduction in the number of patient visits. The imposition of lockdown as a strategy to flatten the curve of COVID-19 patients also stalled the management of these patients. However, currently majority of healthcare departments have recovered and gained the number of patient vesting’s to a standard value.

By Treatment Type
• Drug Treatment
Anti-inflammatories (NSAIDS)
Acetaminophen
Muscle relaxants
Narcotics
Corticosteroids
Others
• Biologics
• Other

By Route of Administration
• Oral
• Injectables
• Other

By End-User
• Hospitals
• Specialty Clinics
• Academic Research Centers
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Key Developments
• In June 2022, a pilot study encountered proof to suggest that pentoxifylline (PTX), when integrated with usual care, may safely relieve short-term radicular pain in patients with degenerative disc disorder.
• In January 2023, DiscGenics, Inc., a clinical-stage biopharmaceutical corporation concentrated on designing cell-based regenerative therapies that relieve pain and repair function in individuals with degenerative conditions of the spine, obtained the U.S. Food and Drug Administration (FDA) Regenerative Medicine Advanced Therapy (RMAT) designation to Injectable Disc Cell Therapy (IDCT or rebonuputemcel), an injectable, allogeneic discogenic progenitor cell therapy to treat symptomatic lumbar degenerative disc disease (DDD).
• In July 2023, Alpha Healthcare Acquisition Corp. III (“ALPA”), a special purpose acquisition corporation merged the business (the “Business Combination”) with Carmell Therapeutics Corporation, a Phase 2 stage regenerative medicine platform corporation producing allogeneic plasma-based biomaterials for active soft tissue repair, aesthetics and orthopedic indications.

Competitive Landscape

The major global players in the market include Sorrento Therapeutics, SpineThera, Eliem Therapeutics, Scilex Holding, Sinfonia Biotherapeutics, Seikagaku Corporation, Kolon life Science, Vita Sciences, Aurobindo Pharma, and Neurotech among others.

Why Purchase the Report?
• To visualize the global lumbar degenerative disc disease market segmentation based on treatment type, route of administration, end-user, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of lumbar degenerative disc disease market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key product of all the major players.

The global lumbar degenerative disc disease market report would provide approximately 61 tables, 58 figures and 186 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies